Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 9, 2002, Pages 493-500

  Kashyap, Ashwin ^a   Wingard, John ^a   Cagnoni, Pablo ^a   Jones, Roy ^a   Tarantolo, Stephan ^a   Hu, Wendy ^a   Blume, Karl ^a   Niland, Joyce ^a   Palmer, Joycelynne M ^a   Vaughan, William ^a   Fernandez, Hugo ^a   Champlin, Richard ^a   Forman, Stephen ^a   Andersson, Borje S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Busulfan; Dose limiting toxicity; Hepatic first pas effect; Myeloablative conditioning regimens; Pharmacokinetics

Indexed keywords

ANTIEMETIC AGENT; ANTITHROMBIN III; BUSULFAN; CYCLOPHOSPHAMIDE; HEPARIN; MESNA; METHOTREXATE; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; BUCY 2 PROTOCOL; BUCY-2 PROTOCOL;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG FATALITY; DRUG FORMULATION; FEMALE; FIRST PASS EFFECT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; INCIDENCE; LIVER; LIVER VENOOCCLUSIVE DISEASE; LIVING DONOR; LOGISTIC REGRESSION ANALYSIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR; SEIZURE; SIBLING; STANDARDIZATION; STATISTICAL ANALYSIS; ALLOTRANSPLANTATION; BLOOD DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER VEIN OBSTRUCTION; METHODOLOGY; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036400369     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12374454     Document Type: Article

References (22)

1. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, Mass; Blackwell Science, Inc; 1999:627-658.
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005-3020.
3. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778-783.
4. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hematology. 1984;4:116.
5. McDonald GB, Hinds MS, Fisher LB, et al. Venooclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993; 118:255-267.
6. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation - etoposide versus busulfan/cyclophosphamide as preparative regimens for bone marrow transplantation in patients with leukemia who were not in first remission: A Southwest Oncology Group study. Blood. 1993;81:2187-2193.
7. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
8. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18-25.
9. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
10. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89: 3055-3060.
11. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
12. Hassan M. Busulphan. In: Grochow LB Ames MM, eds. A Clinical Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. New York, NY: Williams and Wilkins; 1997:189-208.
13. Schuler U, Schroer S, Kuhnle A, Schmidt H, Ehninger G. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant. 1994;14:759-765.
14. Vaughan WP, Cagnoni P, Fernandez H, et al. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan (BU) containing preparative regimen for hematopoietic stem cell transplantation (HSCT). Blood. 1998;92:516a.
15. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382-1388.
16. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000;6:548-554.
17. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996; 37:401-408.
18. Andersson BS, Bhagwatwar H, Chow D, inventors. Parenteral busulfan for treatment of malignant disease. US Patent 5,430,057. 1995. US Patent 5,559,148. 1996.
19. Busulfex® (busulfan) Injection [product monograph]. Minnetonka, Minn: Orphan Medical, Inc; 2001.
20. Bearman SI, Anderson GL, Mori M, et al. Venooclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;9:1729.
21. Cancer Therapy Evaluation Program. Common Toxicity Criteria version 7.0. Available at http://ctep.info.nih.gov.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457.